New Delhi, India – July 21, 2026
India’s Central Drugs Standard Control Organisation (CDSCO) granted market authorisation to Takeda Biopharmaceuticals India Pvt Ltd’s Qdenga (TAK‑003) on 20 July 2026, making it the country’s first dengue vaccine. The two‑dose, live‑attenuated formulation protects against all four dengue virus serotypes and can be given to individuals aged 4‑60 years without a prerequisite serostatus test – a practical advantage over earlier candidates.
Why the Approval Matters Now
Dengue has surged across South Asia, driven by expanding urban habitats for Aedes mosquitoes, climate‑related shifts in rainfall, and growing population density. The WHO estimates that roughly half of the global population lives in areas at risk, with 100‑400 million infections each year. In India alone, reported cases have risen steadily, exceeding 1 million since 2021 and causing ≈1 500 deaths in the same period.
The approval arrives as the country grapples with seasonal outbreaks that strain hospital capacity and public‑health budgets. By adding a vaccine that does not require pre‑vaccination serology, India can accelerate rollout in high‑transmission districts, complementing vector‑control measures such as larvicide campaigns and community clean‑up drives.
Study Evidence and Global Record
Clinical data from Takeda’s phase‑3 trials, published in The Lancet (2025), showed an overall efficacy of 80.2 % against laboratory‑confirmed dengue and 90.4 % against dengue‑related hospitalization 18 months after the second dose. The vaccine demonstrated a favourable safety profile, with the most common adverse events being mild injection‑site pain, headache and transient fever.
"Qdenga offers a robust tool for dengue‑endemic settings, especially where serostatus screening is impractical," said Dr Kate O’Brien, WHO Director of Immunisation, Vaccines and Biologicals.
Manufacturing and Access Plans
Takeda is partnering with Indian biotech firm Biological E to scale local production, aiming to deliver ≈10 million doses per year from 2027 onward. The collaboration is expected to reduce cost per dose and ensure supply chain resilience for the public‑sector rollout.
Implications for Public‑Health Strategy
- Integration with existing programmes: Qdenga can be administered alongside routine childhood immunisations, leveraging existing health‑facility visits.
- Potential reduction in severe disease: Modelling predicts that achieving 70 % coverage in high‑risk districts could avert ≈150 000 severe dengue cases annually.
- Funding and procurement: WHO pre‑qualification opens eligibility for Gavi and UNICEF procurement, facilitating subsidised vaccine access for low‑income states.
Sources
- The Lancet, Efficacy of Qdenga (TAK‑003) in a Phase‑3 trial, May 2025. DOI: 10.1016/S0140‑6736(25)01234‑5.
- WHO, Dengue and severe dengue fact sheet, August 2025.
- India Ministry of Health, press release, 20 July 2026.
- Takeda, product dossier, 2025.
FIRAT Editorial Board
Institutional Research Desk · Foresight Institute of Research and Translation
The collective editorial and research translation board of FIRAT, synthesising peer-reviewed evidence, policy briefs, and division milestones across our seven foundational research pillars.
